Dr. Zelenetz on Nivolumab Plus Ibrutinib in Patients With CLL

Andrew D. Zelenetz, MD, PhD
Published: Tuesday, Apr 25, 2017



Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

A clinical trial of nivolumab combined with ibrutinib was explored in patients with CLL and Richter’s transformation. However, results showed that all of the clinical activity observed with nivolumab was in patients who had Richter’s transformation, but not CLL. The activity observed is what would have been expected ibrutinib to have in patients with CLL.  


Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

A clinical trial of nivolumab combined with ibrutinib was explored in patients with CLL and Richter’s transformation. However, results showed that all of the clinical activity observed with nivolumab was in patients who had Richter’s transformation, but not CLL. The activity observed is what would have been expected ibrutinib to have in patients with CLL.  



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x